Let’s dig into the relative performance of Penumbra (NYSE:PEN) and its peers as we unravel the now-completed Q1 medical devices & supplies - cardiology, neurology, vascular earnings season.

Penumbra delivered the fastest revenue growth but had the weakest full-year guidance update in the group. Interestingly, the stock is up 1.1% since the results and currently trades at $281.56.

Taking into account the latest results, the most recent consensus for Penumbra from 20 analysts is for revenues of US$1.35b in 2025. If met, it would imply a meaningful 9.2% increase on its ...

Penumbra, Inc. and Asahi Intecc Co. will collaborate to introduce Penumbra’s Indigo™ Aspiration System into the Japanese market upon regulatory approval.

Sales of $324.1 million, up 16.3% year over year (+16.9% in constant currency) and beating the consensus of $315.66 million. Adjusted EPS of 83 cents, beating the consensus of 67 cents. Revenue ...

Let’s dig into the relative performance of Penumbra (NYSE:PEN) and its peers as we unravel the now-completed Q1 medical devices & supplies - cardiology, neurology, vascular earnings season. The ...

Penumbra reported revenues of $315.5 million, up 10.8% year on year, outperforming analysts’ expectations by 1.2%.